Chronic Kidney Disease Clinical Trials 2023

What are the top hospitals conducting chronic kidney disease research?

When it comes to advancing the understanding and treatment of chronic kidney disease, several hospitals are making notable contributions through their active clinical trials. In San Antonio, the Clinical Advancement Center, PLLC is at the forefront with four ongoing trials dedicated to chronic kidney disease. This center is committed to exploring new avenues in research for this debilitating condition. Similarly, Vanderbilt University Medical Center in Nashville has three active trials focused on chronic kidney disease. Known for its esteemed reputation in medical research and education, Vanderbilt is playing a crucial role in uncovering innovative approaches to managing this complex disease.

In Waterbury, Chase Medical Research LLC also joins the list with three ongoing clinical trials centered around chronic kidney disease. This facility's dedication to investigating potential treatments speaks volumes about their commitment towards improving outcomes for patients living with this condition.

Meanwhile, Cleveland Clinic located in Cleveland stands out as a leading institution driving progress against chronic kidney disease through three active clinical trials aimed at enhancing our understanding of this ailment and finding effective solutions. Lastly but not least significant is Novo Nordisk Investigational Site situated in San Dimas where they too actively participate by conducting three clinical examinations concentrated on studying severe cases relating to Chronic Kidney Disease (CKD).

These pioneering hospitals across different locations are united by their shared mission: tackling one of humanity’s most challenging health issues - chronic kidney disease; By continually pushing boundaries through rigorous research efforts; these institutions offer hope and promise for individuals affected by CKD worldwide

Which are the best cities for chronic kidney disease clinical trials?

When it comes to chronic kidney disease clinical trials, several cities have emerged as leaders in research and development. Houston, Texas leads the way with 22 active trials investigating treatments like Cohort 2, Doxercalciferol (GZ427397), and Semaglutide. Chicago, Illinois closely follows with 19 ongoing studies focusing on innovations such as Finerenone (BAY94-8862) and various arms of Cohort 2. San Antonio, Texas also shows promising progress with 18 active trials exploring treatments like Semaglutide and CIN-107. Additionally, Los Angeles, California and Kansas City, Missouri each contribute significantly to the field with their own set of active trials examining a range of potential therapies for chronic kidney disease patients. These cities serve as important hubs for cutting-edge research that holds promise for improving care outcomes in this challenging condition.

Which are the top treatments for chronic kidney disease being explored in clinical trials?

Clinical trials are paving the way for groundbreaking treatments in chronic kidney disease (CKD). Among the top contenders is tolvaptan, a medication being explored in four active clinical trials. Another promising option is bardoxolone methyl, currently undergoing evaluation in three ongoing CKD studies. Additionally, sparsentan has generated significant interest with its potential therapeutic benefits and participation in two active trials. These innovative treatments offer hope for patients battling this debilitating condition and signify progress towards improving outcomes and quality of life for individuals affected by CKD.

What are the most recent clinical trials for chronic kidney disease?

Promising advancements in the field of chronic kidney disease (CKD) are emerging through recent clinical trials. One noteworthy study explores an intervention group, undergoing both Phase 1 and Phase 2 trials, aiming to improve CKD management. Another trial focuses on a dedicated Chronic Kidney Disease Group for patients, providing potential insights into effective treatment approaches. Additionally, there is ongoing investigation into the benefits of consuming alkalizing fruit and vegetables as part of managing CKD symptoms. Furthermore, a Phase 2 trial examines LY3437943's efficacy in addressing this condition while Renal Autologous Cell Therapy (REACT), currently undergoing Phase 1 testing, offers hope for innovative therapeutic options moving forward. These studies foster optimism within the CKD community by expanding our understanding and paving the way towards improved care strategies.

What chronic kidney disease clinical trials were recently completed?

Several recent clinical trials have concluded, focusing on advancing treatments for chronic kidney disease (CKD). One notable achievement was the completion of a trial investigating the efficacy of Uproleselan, sponsored by Washington University School of Medicine in October 2021. Additionally, a trial examining mRNA-1273 therapy, led by the National Cancer Institute and completed in September 2021, showcased promising results for CKD patients. These significant milestones highlight ongoing efforts to improve treatment options and outcomes for individuals living with this challenging condition.